Pan Qi, Chen Huan, Fei Sijia, Zhao Peiyi, Deng Mingqun, Xiao Fei, Guo Lixin
Department of Endocrinology, Beijing Hospital, National Center of Gerontology, Institute of Geriatric Medicine, Chinese Academy of Medical Sciences, Beijing 100000, China; Chinese Academy of Medical Sciences & Peking Union Medical College, Beijing 100000, China.
Department of Endocrinology, Beijing Hospital, National Center of Gerontology, Institute of Geriatric Medicine, Chinese Academy of Medical Sciences, Beijing 100000, China.
Diabetes Res Clin Pract. 2023 Dec;206:110980. doi: 10.1016/j.diabres.2023.110980. Epub 2023 Oct 25.
This study aimed to clarify the changes in treatment regimens and medical expenditures in diabetic patients with osteoporosis.
We recruited 2,853,036 diabetic patients from the Beijing medical insurance database between 2016 and 2018. Among them, 406,221 patients also had osteoporosis. Clinical characteristics, treatment regimens, and medical costs were investigated in diabetic patients with and without osteoporosis.
Diabetes and osteoporosis were most prevalent in participants aged 45---84 years. Compared with diabetic patients without osteoporosis, those with osteoporosis were prone to developing comorbidities and diabetic complications. They often required multiple glucose-lowering drugs and had a higher rate of insulin use. Similarly, osteoporosis leads to an increased number of medications for non-hypoglycemia as well as higher healthcare costs. These medications and costs increased with the number of complications and comorbidities. Interestingly, from 2016 to 2018, although diabetic patients with osteoporosis took more drugs, medical costs were lower year by year.
Osteoporosis might contribute to a worse condition in diabetic patients, and this population often requires more medications with higher medical costs.
本研究旨在阐明糖尿病合并骨质疏松症患者治疗方案和医疗费用的变化情况。
我们从2016年至2018年的北京医疗保险数据库中招募了2,853,036名糖尿病患者。其中，406,221名患者还患有骨质疏松症。对患有和未患有骨质疏松症的糖尿病患者的临床特征、治疗方案和医疗费用进行了调查。
糖尿病和骨质疏松症在45至84岁的参与者中最为普遍。与未患骨质疏松症的糖尿病患者相比，患有骨质疏松症的患者更容易出现合并症和糖尿病并发症。他们通常需要多种降糖药物，胰岛素使用率更高。同样，骨质疏松症导致用于非低血糖治疗的药物数量增加，医疗费用也更高。这些药物和费用随着并发症和合并症的数量增加而增加。有趣的是，从2016年到2018年，尽管患有骨质疏松症的糖尿病患者服用的药物更多，但医疗费用却逐年降低。
骨质疏松症可能会使糖尿病患者的病情恶化，并且这一人群通常需要更多药物，医疗费用更高。
